Lantern Pharma Stock Today

LTRN Stock  USD 9.65  0.13  1.33%   

Performance

15 of 100

 
Low
 
High
Good

Odds Of Distress

Less than 42

 
100  
 
Zero
Below Average
Lantern Pharma is selling at 9.65 as of the 28th of March 2024; that is -1.33 percent decrease since the beginning of the trading day. The stock's open price was 9.78. Lantern Pharma has about a 42 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for Lantern Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of September 2023 and ending today, the 28th of March 2024. Click here to learn more.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. The company was incorporated in 2013 and is headquartered in Dallas, Texas. The company has 10.74 M outstanding shares of which 67.96 K shares are now shorted by private and institutional investors with about 0.71 trading days to cover. More on Lantern Pharma

Moving together with Lantern Stock

  0.63MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr
  0.73MDWD Mediwound Financial Report 4th of June 2024 PairCorr

Moving against Lantern Stock

  0.83MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.8KA Kineta Inc Report 29th of March 2024 PairCorr
  0.79MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.78TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
  0.6MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.59DBVT DBV Technologies Financial Report 2nd of May 2024 PairCorr
  0.42MBRX Moleculin Biotech Upward RallyPairCorr

Lantern Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Lantern Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Lantern Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO PresidentPanna Sharma
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Lantern Pharma (LTRN) is traded on NASDAQ Exchange in USA. It is located in 1920 McKinney Avenue, Dallas, TX, United States, 75201 and employs 21 people. Lantern Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 112.25 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lantern Pharma's market, we take the total number of its shares issued and multiply it by Lantern Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Lantern Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.74 M outstanding shares of which 67.96 K shares are now shorted by private and institutional investors with about 0.71 trading days to cover. Lantern Pharma currently holds about 62.15 M in cash with (14.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74.
Check Lantern Pharma Probability Of Bankruptcy
Ownership Allocation
Lantern Pharma holds a total of 10.74 Million outstanding shares. Lantern Pharma secures 15.06 % of its outstanding shares held by insiders and 22.55 % owned by institutional investors. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Lantern Ownership Details

Lantern Stock Price Odds Analysis

Contingent on a normal probability distribution, the odds of Lantern Pharma jumping above the current price in 90 days from now is about 1.06%. The Lantern Pharma probability density function shows the probability of Lantern Pharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Lantern Pharma has a beta of 0.6098. This indicates as returns on the market go up, Lantern Pharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Lantern Pharma will be expected to be much smaller as well. Moreover, lantern Pharma has an alpha of 1.6312, implying that it can generate a 1.63 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 9.65HorizonTargetOdds Above 9.65
98.93%90 days
 9.65 
1.06%
Based on a normal probability distribution, the odds of Lantern Pharma to move above the current price in 90 days from now is about 1.06 (This Lantern Pharma probability density function shows the probability of Lantern Stock to fall within a particular range of prices over 90 days) .

Lantern Pharma Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Lantern Pharma market risk premium is the additional return an investor will receive from holding Lantern Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Lantern Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Lantern Pharma's alpha and beta are two of the key measurements used to evaluate Lantern Pharma's performance over the market, the standard measures of volatility play an important role as well.

Lantern Stock Against Markets

Picking the right benchmark for Lantern Pharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Lantern Pharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Lantern Pharma is critical whether you are bullish or bearish towards Lantern Pharma at a given time. Please also check how Lantern Pharma's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Lantern Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run ETF Categories Now

   

ETF Categories

List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
All  Next Launch Module

Lantern Pharma Corporate Management

Elected by the shareholders, the Lantern Pharma's board of directors comprises two types of representatives: Lantern Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lantern. The board's role is to monitor Lantern Pharma's management team and ensure that shareholders' interests are well served. Lantern Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lantern Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
DVM MSCoFounder AdvisorProfile
Nicole LeberFinance AssociateProfile
MS BSHead OperationsProfile
Kishor BhatiaChief ConsultantProfile

How to buy Lantern Stock?

Before investing in Lantern Pharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Lantern Pharma. To buy Lantern Pharma stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Lantern Pharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Lantern Pharma stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Lantern Pharma stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Lantern Pharma stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Lantern Pharma, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Lantern Stock please use our How to Invest in Lantern Pharma guide.

Already Invested in Lantern Pharma?

The danger of trading Lantern Pharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Lantern Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Lantern Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Lantern Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.

Complementary Tools for Lantern Stock analysis

When running Lantern Pharma's price analysis, check to measure Lantern Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lantern Pharma is operating at the current time. Most of Lantern Pharma's value examination focuses on studying past and present price action to predict the probability of Lantern Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lantern Pharma's price. Additionally, you may evaluate how the addition of Lantern Pharma to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Equity Valuation
Check real value of public entities based on technical and fundamental data
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Is Lantern Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.